Cohance Lifesciences Ltd.
COHANCE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹152.28.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%3.8%
- ✓Low debt (D/E < 0.5)0.10x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-26%
- ✕Earnings growing-89%
- ✕Net margin ≥ 10%7.9%
- ✓Current ratio > 1.52.83
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.83
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 6.83.
Weaknesses
- •Low return on equity (3.8%).
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Earnings contracting year on year.
- •Trades ~55% above our estimated fair value.
About Cohance Lifesciences Ltd.
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosi
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.